Ironwood Pharmaceuticals IRWD Proceeds from exercises of stock options and other stock issuances
Proceeds from exercises of stock options and other stock issuances at other companies
Other financials
Where this comes from
Reported directly by Ironwood Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions.
The official record: Ironwood Pharmaceuticals’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ironwood Pharmaceuticals's proceeds from exercises of stock options and other stock issuances.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ironwood Pharmaceuticals's proceeds from exercises of stock options and other stock issuances?
- Ironwood Pharmaceuticals (IRWD) reported proceeds from exercises of stock options and other stock issuances of $122K in Q4 2025.
- How has Ironwood Pharmaceuticals's proceeds from exercises of stock options and other stock issuances changed year-over-year?
- Ironwood Pharmaceuticals's proceeds from exercises of stock options and other stock issuances decreased by 39.9% year-over-year, from $203K to $122K.
- What is the long-term trend for Ironwood Pharmaceuticals's proceeds from exercises of stock options and other stock issuances?
- Over 3 years (2021 to 2025), Ironwood Pharmaceuticals's proceeds from exercises of stock options and other stock issuances has grown at a -77.7% compound annual growth rate (CAGR), from $19.58M to $216K.